Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD53 Monoclonal Antibody (7A8D3)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA548415
Description
CD53 Monoclonal Antibody for Western Blot, ICC/IF, IHC (P), Flow, ELISA
CD53 is a tetraspanin family transmembrane glycoprotein expressed in the lymphoid-myeloid lineage. This molecule has been reported to form complexes with other leukocyte surface proteins such as CD2, CD19, CD21, MHC II, VLA-4 or tetraspanins CD37, CD81 and CD82, thus probably modulating various signaling processes. CD53 is involved in radioresistancy of tumor cells and its triggering has anti-apoptotic effect. In thymus, CD53 is up-regulated in response to positive selection signals during T cell development, and is strongly expressed upon macrophage exposure to bacterial lipopolysaccharide, whereas stimulation of neutrophils results in down-regulation of CD53 expression.
Specifications
CD53 | |
Monoclonal | |
1 mg/mL | |
PBS with 0.05% sodium azide | |
P19397 | |
Cd53 | |
Purified recombinant fragment of human CD53 (AA: extra mix) expressed in E. Coli. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG2a |
ELISA, Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
7A8D3 | |
Unconjugated | |
Cd53 | |
AI323659; antigen MOX44 identified by monoclonal antibody MRC-OX44; Cd53; CD53 antigen; CD53 glycoprotein; CD53 molecule; CD53 tetraspan antigen; cell surface antigen; cell surface glycoprotein CD53; Leukocyte antigen MRC OX-44; leukocyte surface antigen CD53; MOX44; OX44; Ox-44; tetraspanin-25; transmembrane glycoprotein; TSPAN25; tspan-25 | |
Mouse | |
Protein G | |
RUO | |
963 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction